Patient advocate Austin Leclaire, who died Feb. 1, played a pivotal role in spurring the development of the first medicines ...
Over the last 7 days, the United States market has remained flat, yet it is up 22% over the past year with earnings expected to grow by 15% per annum in the coming years. In this context of steady ...
Some see visions of resplendent light, while others are taunted with ominous warnings from the shadows. One thing is clear: something is coming, as a sinister threat rises from within Azeroth itself.
Percheron Therapeutics says it will abandon its lead drug candidate altogether, following December's Duchenne muscular dystrophy trial flop. ... Read More The post Health Check: Percheron ‘closes the ...
CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...
Students from the Thomas Edison EnergySmart Charter School in Somerset, New Jersey, will have the chance to connect with NASA astronaut Nick Hague as he answers prerecorded science, technology, ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...
The BMI team was thrilled to attend the 2025 CSU Fresno Geomatics Conference, held this January. As a premier event for land surveying professionals in California, the conference was hosted by Fresno ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...
Advocates and providers are pushing back against Gov. Tim Walz’s proposed disability service changes and remain wary of ...
Shares of Cumberland Pharmaceuticals continued their eye-opening ascent Wednesday on heavy volume.
Duchenne muscular dystrophy (DMD) treatment ifetroban led to improvements in measures of heart function in a Phase 2 clinical ...